CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00383331
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:34:59.309650+00:00
Published At: 2009-05-14T00:00:00+00:00
Record Updated At: 2009-06-03
Results Posted At: 2009-05-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Small-Cell Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2009-06-03"
protocolSection.identificationModule.nctId: "NCT00383331"
protocolSection.identificationModule.officialTitle: "A Phase II Study of ALIMTA\u00ae (Pemetrexed) and GEMZAR\u00ae (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2009-05-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.